Cargando…

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma

SIMPLE SUMMARY: Deleterious mutations in SWI/SNF chromatin remodeling genes, such as ARID1A, are present in more than 50% of cases of ovarian clear cell carcinoma (OCCC), a histological subtype of ovarian cancer prevalent in Asian countries. To efficiently treat OCCC, which is refractory to conventi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Kazuaki, Takenaka, Masataka, Okamoto, Aikou, Bowtell, David D. L., Kohno, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068058/ https://www.ncbi.nlm.nih.gov/pubmed/33917230 http://dx.doi.org/10.3390/cancers13081769

Ejemplares similares

MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma
por: Yanaihara, Nozomu, et al.
Publicado: (2016)

Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
por: Seki, Toshiyuki, et al.
Publicado: (2021)

MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
por: Yokomizo, Ryo, et al.
Publicado: (2019)

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
por: Choi, Jae Yoon, et al.
Publicado: (2017)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
por: Sato, Emi, et al.
Publicado: (2018)

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
por: Maeda, Daichi, et al.
Publicado: (2010)

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
por: Ge, Huijuan, et al.
Publicado: (2021)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
por: Berns, Katrien, et al.
Publicado: (2018)

CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma
por: Kawahara, Naoki, et al.
Publicado: (2021)

CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells
por: Kawabata, Ayako, et al.
Publicado: (2022)

Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
por: Yano, Mitsutake, et al.
Publicado: (2019)

SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
por: Wagner, Samantha Kay, et al.
Publicado: (2023)

MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma
por: Hirata, Yukihiro, et al.
Publicado: (2014)

Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma
por: Okamoto, Aikou, et al.
Publicado: (2015)

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level
por: Goldman, Aaron R., et al.
Publicado: (2016)

Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma
por: Jung, Un Suk, et al.
Publicado: (2020)

ARID1A gene mutation in ovarian and endometrial cancers (Review)
por: TAKEDA, TAKASHI, et al.
Publicado: (2016)

The Tumor Microenvironment of Clear-Cell Ovarian Cancer
por: Devlin, Michael-John, et al.
Publicado: (2022)

PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma
por: Morikawa, Asuka, et al.
Publicado: (2018)

A multi‐ethnic analysis of immune‐related gene expression signatures in patients with ovarian clear cell carcinoma
por: Heong, Valerie, et al.
Publicado: (2021)

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
por: Alldredge, Jill K., et al.
Publicado: (2017)

AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells
por: Lee, Dakeun, et al.
Publicado: (2017)

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
por: Clemente, Valentino, et al.
Publicado: (2022)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
por: Amano, Tsukuru, et al.
Publicado: (2021)

Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis
por: Suda, Kazuaki, et al.
Publicado: (2020)

Targeting the Metabolic Vulnerability of ARID1A-Deficient Hepatocellular Carcinoma
por: Chan, For-Fan, et al.
Publicado: (2022)

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report
por: Zhao, Yingchao, et al.
Publicado: (2022)

Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma
por: Tanaka, Tamaki, et al.
Publicado: (2022)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma
por: Tamura, Ryo, et al.
Publicado: (2022)

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
por: Lin, Yu-Chien, et al.
Publicado: (2020)

ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis
por: Yachida, Nozomi, et al.
Publicado: (2020)

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
por: Kinose, Yasuto, et al.
Publicado: (2023)

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
por: Yakovlev, Vasily A., et al.
Publicado: (2023)

Nodal induces apoptosis and inhibits proliferation in ovarian endometriosis-clear cell carcinoma lesions
por: Miura, Rinako, et al.
Publicado: (2019)

ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma
por: Megino‐Luque, Cristina, et al.
Publicado: (2022)

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
por: Kondo, Eiji, et al.
Publicado: (2020)

Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma
por: Yamazaki, Hiroyuki, et al.
Publicado: (2018)

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
por: Chien, Wenwen, et al.
Publicado: (2023)

Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination
por: Nakamura, Eriko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uflr50qb042irf5v42349719rc